Skip to content

Protokin therapy in the management of painful bladder syndrome/interstitial cystitis: A pilot study

Protokin therapy in the management of painful bladder syndrome/interstitial cystitis: A pilot study

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20130306012728N9
Enrollment
10
Registered
2023-11-05
Start date
2023-09-03
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

Interventions

Intervention group: Protokin therapy. 10 cc of blood is taken from the patient (using a protokine syringe) and incubated at 37 oc for 6-9 hours and centrifuged at 5000 rpm for 6 minutes. Finally, 4.5

Sponsors

Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: All patients with painful bladder syndrome/interstitial cystitis who were resistant to first, second and third line treatment (Botox injection). Patients who had urodynamic evaluation before injection

Exclusion criteria

Exclusion criteria: Lack of consent to participate in the study

Design outcomes

Primary

MeasureTime frame
BPIC-SS questionnaire scores. Timepoint: Before and 1 and 3 months after injection. Method of measurement: BPIC-SS questionnaire.;Determining the level of patients' satisfaction with the intervention. Timepoint: Before and 1 and 3 months after injection. Method of measurement: Based on the evaluation checklist, the patient's satisfaction with the procedure is measured from completely satisfied to completely dissatisfied: the evaluated questions include: completely satisfied, somewhat satisfied, dissatisfied, completely dissatisfied.;Determining the amount of side effects in patients. Timepoint: 1 and 3 months after injection. Method of measurement: Checklist for any side effects.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSakineh hajebrahimi

Tabriz University of Medical Sciences

hajebrahimis@gmail.com+98 41 3334 2219

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026